Impact of pre-treatment lactate dehydrogenase levels on prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Passardi, Alessandro ^a   Scarpi, Emanuela ^a   Tamberi, Stefano ^b   Cavanna, Luigi ^c   Tassinari, Davide ^d   Fontana, Annalisa ^e   Pini, Sara ^a   Bernardini, Ilaria ^f   Accettura, Caterina ^g   Ulivi, Paola ^a   Frassineti, Giovanni Luca ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b Degli Infermi Hospital   (Italy)

^c GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^d Ospedale Per Gli Infermi   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f Ramazzini Hospital   (Italy)

^g VITO FAZZI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; BLOOD; CLINICAL TRIAL; COLON; COLORECTAL NEOPLASMS; DRUG EFFECTS; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; RECTUM; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COLON; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LACTATE DEHYDROGENASES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECTUM; TREATMENT OUTCOME;

EID: 84941955861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134732     Document Type: Article

References (22)

1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400. PMID: 15136787
2. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life. 2013; 65: 904-910. doi: 10.1002/iub.1216 PMID: 24265197
3. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem. 2010; 17: 672-697. PMID: 20088761
4. Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012; 106: 799-804. doi: 10.1038/bjc.2012.17 PMID: 22315053
5. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: Final results for first line treatment from the ITACA randomized clinical trial. Ann Oncol. 2015; 26: 1201-1207. doi: 10.1093/annonc/mdv130 PMID: 25735317
6. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol. 1991; 9: 211-219. PMID: 1703226
7. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991; 115: 931-935. PMID: 1952489
8. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001; 24: 547-550. PMID: 11801751
9. Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol. 2001; 24: 376-378. PMID: 11474266
10. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009; 45: 1807-1814. doi: 10.1016/j.ejca.2009.04.016 PMID: 19419855
11. Kemeny N, Braun DW Jr. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med. 1983; 74: 786-794. PMID: 6837602
12. De Gramont A, Figer A, Seymur M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16):2938-2947. PMID: 10944126
13. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343: 905-914. PMID: 11006366
14. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237. PMID: 14657227
15. Watine J, Friedberg B. Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin Chim Acta. 2004; 345: 1-15. PMID: 15193973
16. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, et al. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with firstline irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer. 2005; 5: 197-202. PMID: 16197623
17. Lin JT, Wang WS, Yen CC, Liu JH, Yang MH, Chao TC, et al. Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol. 2005; 20: 900-905. PMID: 15946138
18. Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isikdogan A et al. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pac J Cancer Prev. 2012; 13: 1059-1063. PMID: 22631638
19. Bar J, Spencer S, Morgan S, Brooks L, Cunningham D, Robertson J, et al. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advancedcolorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study. Clin Colorectal Cancer 2014; 13: 46-53. doi: 10.1016/j.clcc.2013.11.002 PMID: 24355210
20. Major P, Trarbach T, Lenz H, Kerr D, Pendergrass K, Douillard J, et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. J Clin Oncol. (ASCO Annual Meeting Proceedings Abstracts) 2006; 24 (18suppl): 3529.
21. Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, et al. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014; 7: 1415-1422. doi: 10.2147/OTT.S64559 PMID: 25143746
22. Silvestris N, Scartozzi M, Giusi G, Santini D, Lorusso V, Maiello E, et al. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther 2015; 15: 55-162.